Race Oncology Limited
Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company's lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need… Read more
Market Cap & Net Worth: Race Oncology Limited (RAONF)
Race Oncology Limited (PINK:RAONF) has a market capitalization of $211.97 Million ($211.97 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #16561 globally and #6365 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Race Oncology Limited's stock price $1.22 by its total outstanding shares 173744000 (173.74 Million).
Race Oncology Limited Market Cap History: 2021 to 2025
Race Oncology Limited's market capitalization history from 2021 to 2025. Data shows change from $451.73 Million to $211.97 Million (-20.46% CAGR).
Race Oncology Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Race Oncology Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
52.95x
Race Oncology Limited's market cap is 52.95 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $451.73 Million | $387.38K | -$6.34 Million | 1166.11x | N/A |
| 2022 | $251.93 Million | $707.81K | -$11.20 Million | 355.93x | N/A |
| 2023 | $251.93 Million | $3.13 Million | -$9.92 Million | 80.39x | N/A |
| 2024 | $211.97 Million | $4.00 Million | -$13.82 Million | 52.95x | N/A |
Competitor Companies of RAONF by Market Capitalization
Companies near Race Oncology Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Race Oncology Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Race Oncology Limited Historical Marketcap From 2021 to 2025
Between 2021 and today, Race Oncology Limited's market cap moved from $451.73 Million to $ 211.97 Million, with a yearly change of -20.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $211.97 Million | 0.00% |
| 2024 | $211.97 Million | -15.86% |
| 2023 | $251.93 Million | 0.00% |
| 2022 | $251.93 Million | -44.23% |
| 2021 | $451.73 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Race Oncology Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $211.97 Million USD |
| MoneyControl | $211.97 Million USD |
| MarketWatch | $211.97 Million USD |
| marketcap.company | $211.97 Million USD |
| Reuters | $211.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.